The estimated Net Worth of Herman Paul Pressler is at least $26 mil dollars as of 25 April 2012. Herman Pressler owns over 5,000 units of Galectin Therapeutics Inc stock worth over $26,030 and over the last 13 years Herman sold GALT stock worth over $0.
Herman has made over 1 trades of the Galectin Therapeutics Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Herman bought 5,000 units of GALT stock worth $15,500 on 25 April 2012.
The largest trade Herman's ever made was buying 5,000 units of Galectin Therapeutics Inc stock on 25 April 2012 worth over $15,500. On average, Herman trades about 1,667 units every 0 days since 2012. As of 25 April 2012 Herman still owns at least 9,500 units of Galectin Therapeutics Inc stock.
You can see the complete history of Herman Pressler stock trades at the bottom of the page.
Herman's mailing address filed with the SEC is C/O GALECTIN THERAPUTICS INC., 7 WELLS AVENUE, SUITE 34, NEWTON, MA, 02459.
Over the last 14 years, insiders at Galectin Therapeutics Inc have traded over $21,823,082 worth of Galectin Therapeutics Inc stock and bought 5,077,107 units worth $21,362,250 . The most active insiders traders include Richard E Uihlein, James C Czirr y Fund, L.P.10 X Capital Mana.... On average, Galectin Therapeutics Inc executives and independent directors trade stock every 27 days with the average trade being worth of $226,012. The most recent stock trade was executed by Richard A. Jr. Zordani on 22 August 2024, trading 3,500 units of GALT stock currently worth $8,050.
galectin therapeutics (nasdaq: galt) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. drug candidates based on the company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pathologic function. we use naturally occurring carbohydrate polymers with galactose residues to create complex carbohydrates with specific molecular weights. using these unique carbohydrate-based candidate compounds that bind and inhibit galectin proteins, we are pursuing therapies for indications where galectins have a demonstrated role in the pathogenesis of a particular disease. we focus on diseases with serious, life threatening consequences to patients, and those where current treatment options are limited. our strategy is to establish clinical development approaches that add value to the company in the shortest time possible, and to seek partners as the program advances and requires much
Galectin Therapeutics Inc executives and other stock owners filed with the SEC include: